Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Two Kovsie women involved in international sports events
2012-05-14

 

Hetsie Veitch and Ebeth Grobbelaar
Photo: René-Jean van der Berg
14 May 2012

The organisers of two international sports events will depend on the expertise of two Kovsie women to make the events a major success.

The honour to be involved in international sports event has befallen Ms Hetsie Veitch and Ms Ebeth Grobbelaar.

The honour is the result of many years’ hard work and devotion in their respective fields.

In June, when the USA chooses the team to represent it at the 2012 Paralympic Games in London, Ms Veitch will be one of the classifiers who will determine in which categories athletes may compete.

Ms Veitch, Head of the Unit for Students with Disabilities at the University of the Free State (UFS), has been invited to be a member of the Classification Panel at the final USA Paralympic athletics trials. The trials take place from 27 June to 1 July 2012 in Indianapolis, Indiana, in the USA.

Ms Veitch and four other classifiers, two from Brazil, one from Canada and one from the USA, will test and verify the international classification status of the American athletes. No athlete will be allowed to take part without their classification being verified by the panel.

Ms Veitch, who recently achieved the status of International Paralympic Committee (IPC) Athletics Classifier, the highest achievement for a classifier in sport for the disabled, said that this category of sport has always been her passion.

“To have the opportunity to be involved in the classification of the USA team for the London 2012 Paralympic Games is a huge honour. I am going to start working on being chosen for the official IPC classification panel for the 2016 Paralympic Games in Brazil.”

Ms Grobbelaar, Assistant Director of the South African Testing Laboratory for Prohibited Substances at the UFS, was invited to be involved in the Drugs Control Centre in the unit against prohibited substances which will test sportsmen and women during this year’s Olympic Games in London.

Ms Grobbelaar said that even though the future of sportsmen and women would be in her hands, she is totally capable of carrying out the task that awaits her.

“I will be part of the laboratory team who will test the athletes’ samples for prohibited substances. I was part of the South African team who tested samples in our own laboratory in 2010 during the FIFA Soccer World Cup, as well as for the All Africa Games. The task is one I perform every day in our own laboratories. Each sample that I analyse determines an athlete’s future. The circumstances during the Olympic Games are different, but the work remains the same.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept